CO5180536A1 - CATEPSIN PROTEASE INHIBITORS - Google Patents
CATEPSIN PROTEASE INHIBITORSInfo
- Publication number
- CO5180536A1 CO5180536A1 CO00023372A CO00023372A CO5180536A1 CO 5180536 A1 CO5180536 A1 CO 5180536A1 CO 00023372 A CO00023372 A CO 00023372A CO 00023372 A CO00023372 A CO 00023372A CO 5180536 A1 CO5180536 A1 CO 5180536A1
- Authority
- CO
- Colombia
- Prior art keywords
- alkyl
- group
- het
- alkenyl
- catepsin
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D321/00—Heterocyclic compounds containing rings having two oxygen atoms as the only ring hetero atoms, not provided for by groups C07D317/00 - C07D319/00
- C07D321/12—Eight-membered rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
Abstract
Un compuesto de Fórmula I: <EMI FILE="00023372_1" ID="1" IMF=JPEG >en la cual: R1 se selecciona del grupo constituido por: R", R"C(O), R"C(S), R"SO2, R"OC(O), R"R´NC(O), y R"OC(O)NR´CH(R6)C(O);R2 se selecciona del grupo constituido por: H, alquilo C1-6, alquenilo C2-6, Ar-alquilo C0-6, y Het-alquilo C0-6; R3 se selecciona del grupo constituido por: H, alquilo C1-6, alquenilo C2-6, alquinilo C2-6, cicloalquil C3-6-alquiloC0-6, Ar-alquilo C0-6, y Het-alquilo C0-6;R4 se selecciona del grupo constituido por: H, alquilo C1-6, alquenilo C2-6, Ar-alquilo C0-6, y Het-alquilo C0-6;R5 se selecciona del grupo constituido por: H, alquilo C1-6, alquenilo C2-6, Ar-alquilo C0-6, y Het-alquilo C0-6; R6 se selecciona del grupo constituido por: H, alquilo C1-6, alquenilo C2-6, cicloalquil C3-6-alquilo C0-6, Ar-alquilo C0-6 y Het-alquilo C0-6;R7 se selecciona del grupo constituido por: H, alquilo C1-6, alquenilo C2-6, cicloalquil C3-6, -alquilo C0-6, Ar-alquilo C0-6 y Het-alquilo C0-6; R8 se selecciona del grupo constituido por: H, alquilo C1-6, alquenilo C2-6, cicloalquil C3-6 -alquilo C0-6, Ar-alquilo C0-6, y Het-alquilo C0-6;R´ se selecciona del grupo constituido por: H, alquilo C1-6, alquenilo C2-6, Ar-alquilo C0-6, y Het-alquilo C0-6; R" se selecciona del grupo constituido por: alquilo C1-6, Ar-alquilo C0-6, Het-alquilo C0-6, Ar-alquenilo C2-6 y Hetalquenilo C2-6;X se selecciona del grupo constituido por: 0 y S; e Y se selecciona del grupo constituido por: 0 y S; y sus sales, hidratos y solvatos farmacéuticamente aceptables.A compound of Formula I: <EMI FILE = "00023372_1" ID = "1" MFI = JPEG> in which: R1 is selected from the group consisting of: R ", R" C (O), R "C (S) , R "SO2, R" OC (O), R "R´NC (O), and R" OC (O) NR´CH (R6) C (O); R2 is selected from the group consisting of: H, alkyl C1-6, C2-6 alkenyl, Ar-C0-6 alkyl, and Het-C0-6 alkyl; R3 is selected from the group consisting of: H, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, cycloalkyl C3-6-C0-6 alkyl, Ar-C0-6 alkyl, and Het-C0-6 alkyl; R4 is selected from the group consisting of: H, C1-6 alkyl, C2-6 alkenyl, Ar-C0-6 alkyl, and Het-C0-6 alkyl; R5 is selected from the group consisting of: H, C1-6 alkyl, C2-6 alkenyl, Ar-C0-6 alkyl, and Het-C0-6 alkyl; R6 is selected from the group consisting of : H, C1-6 alkyl, C2-6 alkenyl, C3-6 cycloalkyl-C0-6 alkyl, Ar-C0-6 alkyl and Het-C0-6 alkyl; R7 is selected from the group consisting of: H, C1- alkyl 6, C2-6 alkenyl, C3-6 cycloalkyl, C0-6 alkyl, Ar-C0-6 alkyl and Het-C0-6 alkyl; R8 was selected a of the group consisting of: H, C1-6 alkyl, C2-6 alkenyl, C3-6 cycloalkyl-C0-6 alkyl, Ar-C0-6 alkyl, and Het-C0-6 alkyl; R 'is selected from the group consisting by: H, C1-6 alkyl, C2-6 alkenyl, Ar-C0-6 alkyl, and Het-C0-6 alkyl; R "is selected from the group consisting of: C1-6 alkyl, Ar-C0-6 alkyl, Het-C0-6 alkyl, Ar2-6 alkenyl and C2-6 hetalkenyl; X is selected from the group consisting of: 0 and S; and Y is selected from the group consisting of: 0 and S; and its pharmaceutically acceptable salts, hydrates and solvates.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US12725099P | 1999-03-31 | 1999-03-31 |
Publications (1)
Publication Number | Publication Date |
---|---|
CO5180536A1 true CO5180536A1 (en) | 2002-07-30 |
Family
ID=22429122
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CO00023372A CO5180536A1 (en) | 1999-03-31 | 2000-03-31 | CATEPSIN PROTEASE INHIBITORS |
Country Status (8)
Country | Link |
---|---|
EP (1) | EP1173429A4 (en) |
JP (1) | JP2002540199A (en) |
AU (1) | AU4066900A (en) |
CO (1) | CO5180536A1 (en) |
HK (1) | HK1044758A1 (en) |
PE (1) | PE20001607A1 (en) |
UY (1) | UY26088A1 (en) |
WO (1) | WO2000058296A1 (en) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20030144175A1 (en) | 1998-12-23 | 2003-07-31 | Smithkline Beecham Corporation | Protease inhibitors |
WO2001034599A1 (en) | 1999-11-10 | 2001-05-17 | Smithkline Beecham Corporation | Protease inhibitors |
AU1474801A (en) | 1999-11-10 | 2001-06-06 | Smithkline Beecham Corporation | Protease inhibitors |
JP2003513972A (en) | 1999-11-10 | 2003-04-15 | スミスクライン・ビーチャム・コーポレイション | Protease inhibitor |
SK13632002A3 (en) | 2000-03-21 | 2003-02-04 | Smithkline Beecham Corporation | C1-6-alkyl-4-amino-azepan-3-one compounds, process for the preparation thereof, pharmaceutical composition comprising the same and intermediates |
US7282512B2 (en) | 2002-01-17 | 2007-10-16 | Smithkline Beecham Corporation | Cycloalkyl ketoamides derivatives useful as cathepsin K inhibitors |
JP2004196696A (en) * | 2002-12-18 | 2004-07-15 | Kyowa Hakko Kogyo Co Ltd | Arthritis-preventing or treating agent |
CN113651795B (en) * | 2021-09-14 | 2022-09-02 | 江西开源香料有限公司 | Synthesis method of watermelon ketone |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5374623A (en) * | 1992-08-20 | 1994-12-20 | Prototek, Inc. | Cysteine protease inhibitors effective for in vivo use |
-
2000
- 2000-03-29 UY UY26088A patent/UY26088A1/en not_active Application Discontinuation
- 2000-03-31 CO CO00023372A patent/CO5180536A1/en not_active Application Discontinuation
- 2000-03-31 AU AU40669/00A patent/AU4066900A/en not_active Abandoned
- 2000-03-31 WO PCT/US2000/008833 patent/WO2000058296A1/en not_active Application Discontinuation
- 2000-03-31 JP JP2000607999A patent/JP2002540199A/en not_active Withdrawn
- 2000-03-31 EP EP00920078A patent/EP1173429A4/en not_active Withdrawn
- 2000-03-31 PE PE2000000283A patent/PE20001607A1/en not_active Application Discontinuation
-
2002
- 2002-06-21 HK HK02104641.3A patent/HK1044758A1/en unknown
Also Published As
Publication number | Publication date |
---|---|
JP2002540199A (en) | 2002-11-26 |
PE20001607A1 (en) | 2001-03-07 |
EP1173429A1 (en) | 2002-01-23 |
EP1173429A4 (en) | 2002-06-19 |
AU4066900A (en) | 2000-10-16 |
UY26088A1 (en) | 2000-10-31 |
WO2000058296A1 (en) | 2000-10-05 |
HK1044758A1 (en) | 2002-11-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO20013379L (en) | 4-oxo-1,4-dihydro-3-quinolinecarboxamides as antiviral agents | |
AR006720A1 (en) | A COMPOUND DERIVED FROM HETERO-CYCLIC AZAHEXANE, ITS USE FOR THE PREPARATION OF A PHARMACEUTICAL COMPOSITION, PROCEDURE FOR PREPARING IT AND A PHARMACEUTICAL COMPOSITION THAT INCLUDES IT | |
DE60135862D1 (en) | ALIPHATIC NITROGEN-CONTAINING FIVE-GLASS RING COMPOUNDS | |
AR240929A2 (en) | N-pyridinsulphonyl-n<<'-pyridinyl and -triazinyl ureas: process for the preparation thereof, intermediates for exclusive use in said process and compositions that contain said ureas | |
CO5200785A1 (en) | THERAPEUTIC USE OF QUINAZOLINE | |
CO5550421A2 (en) | INDOL DERIVATIVES USEFUL FOR THE TREATMENT OF DISEASE | |
ATE288895T1 (en) | GROWTH HORMONE RELEASING OXINDOL DERIVATIVES | |
FI883669A (en) | 1 - / (4-PIPERIDINYL) METHYL / -1,2,3,4-TETRAHYDRO-9H-PYRIDO / 3.4-B / INDOLDERIVAT, DERAS FRAMSTAELLNING OCH TERAPEUTISKA ANVAENDNING. | |
BG103258A (en) | Azinyloxy- and phenoxydiaryl derivatives of carboxylic acids, their preparation and application as mixed eta/etb endothelin-receptor antagonists | |
CO5261565A1 (en) | INHIBITORS OF N- (5 - (((5-RENT-2-OXAZOLIL) METHYL) TIO) -2-TIAZOLIL) -CARBOXAMIDE OF CYCLINE DEPENDENT KINASES | |
CO5180536A1 (en) | CATEPSIN PROTEASE INHIBITORS | |
DE60121587D1 (en) | CYCLIC GMP SPECIFIC PHOSPHODIESTERASE INHIBITORS | |
TW200505446A (en) | Inhibitor of cox | |
CO5271679A1 (en) | PROTEASA INHIBITORS 7-14 MEMBERS | |
EA200101230A1 (en) | NEW INHIBITORS OF METALLOPROTEASIS, THEIR METHOD OF OBTAINING AND CONTAINING THEIR PHARMACEUTICAL COMPOSITIONS | |
CO5180541A1 (en) | PROTEASE INHIBITORS OF THE 1,3-DIAMINOCETONE TYPE WITH 8-14 MEMBER RING | |
CO5080761A1 (en) | INHIBITORS OF LAD FKBP NA INHIBITORS OF THE FKBP | |
EA200400666A2 (en) | New benzothiazine and benzothiadiazine compounds, a process for their preparation and pharmaceutical compositions containing them | |
FI971177A (en) | Bicyclic carboxamides as 5-HT1A antagonists | |
CO5080787A1 (en) | ISOQUINOLINS | |
DK0435235T3 (en) | New isoquinoline derivatives and salts thereof | |
CO5150177A1 (en) | HYDRAZINE DERIVATIVES | |
TW200510300A (en) | Amino alcohol compounds | |
CO5140120A1 (en) | 4-AMINO-AZEPAN-3-ONA PROTEASE INHIBITORS | |
CO5280091A1 (en) | PROTEASE INHIBITORS |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FA | Application withdrawn |